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Abstract
Background: The use of shRNAs to downregulate the expression of specific genes is now relatively
routine in experimentation but still hypothetical for clinical application. A potential therapeutic approach
for HIV-1 disease is shRNA mediated downregulation of the HIV-1 co-receptor, CCR5. It is increasingly
recognized that siRNAs and shRNAs can have unintended consequences such as cytotoxicities in cells,
particularly when used for long term therapeutic purposes. For the clinical use of shRNAs, it is crucial to
identify a shRNA that can potently inhibit CCR5 expression without inducing unintended cytotoxicities.
Results: Previous shRNAs to CCR5 identified using conventional commercial algorithms showed
cytotoxicity when expressed using the highly active U6 pol III promoter in primary human peripheral blood
derived mononuclear cells. Expression using the lower activity H1 promoter significantly reduced toxicity,
but all shRNAs also reduced RNAi activity. In an effort to identify shRNAs that were both potent and non-
cytotoxic, we created a shRNA library representing all potential CCR5 20 to 22-nucleotide shRNA
sequences expressed using an H1 promoter and screened this library for downregulation of CCR5. We
identified one potent CCR5 shRNA that was also non-cytotoxic when expressed at a low level with the
H1 promoter. We characterized this shRNA in regards to its function and structure. This shRNA was
unique that the use of commercial and published algorithms to predict effective siRNA sequences did not
result in identification of the same shRNA. We found that this shRNA could induce sequence specific
reduction of CCR5 at post transcriptional level, consistent with the RNA interference mechanism.
Importantly, this shRNA showed no obvious cytotoxicity and was effective at downregulating CCR5 in
primary human peripheral blood derived mononuclear cells.
Conclusion: We report on the characterization of a rare shRNA with atypical structural features having
potent RNAi activity specific to CCR5. These results have implications for the application of RNAi
technology for therapeutic purposes.
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A finding with critical bearing upon HIV-1 disease was the
fact that individuals homozygous for a defective CCR5
gene, CCR5Δ32, are protected from HIV infection and
heterozygous individuals have a substantially prolonged
course of disease[1,2]. If one could mimic the natural sit-
uation by genetic knockdown of CCR5, a potential ther-
apy could be developed. The ultimate application of gene
therapy for HIV-1 disease would be to introduce gene
therapeutic elements as transgenes into a hematopoietic
stem cell. Transplantation of such a stem cell would result
in reconstitution of a hematopoietic system that in theory
would be protected from the effects of HIV-1. The first step
is the identification of effective reagents that can reduce
CCR5 without unintended cytotoxicity.
Silencing of genes through homologous double stranded
RNA is a sequence specific, highly conserved mechanism.
It serves as an antiviral defense mechanism[3] and pro-
tects cells from retrotransposition[4,5]. siRNAs have been
utilized experimentally to knock out gene expression from
cellular and viral genes [6-10]. A RNA induced silencing
complex (RISC) uses a siRNA as a guide sequence to
cleave the target mRNA at the homologous sequence
resulting in a decrease in the steady-state levels of target
mRNA. Chemically synthesized siRNAs have been utilized
to inhibit various virus infections including HIV-1[8,11].
siRNAs have also been expressed using plasmid vec-
tors[6,9,12-14]. The antiviral effects of siRNA are
sequence specific and differ from previously reported anti-
sense mechanisms or to interferon and interferon
response effectors protein kinase R (PKR) and RNa-
seL[15]. siRNA provides an attractive alternative to other
gene therapeutic reagents due to its small size, and ease of
manipulation. Although, the requirement for an effective
siRNA are not completely understood, our experience and
that of others indicate that choice of siRNAs based upon
published guidelines[6,7] and our own experience will
result in about one third of the sequences being effective
at downregulation to some extent. However, nearly all
shRNAs have cytotoxicity in primary peripheral blood
lymphocytes that is non-target specific, even when
directed to irrelevant sequences such as those of lacZ and
luciferase [16]. The cytotoxic effect is dependent on the
expression of relatively higher levels of shRNA. Lower
expression levels eliminate or reduce cytotoxicity, but also
reduce the potency of downregulation. The mechanism of
the cytotoxicity was in part due to apoptosis. In other
studies, high level expression of shRNAs from adeno asso-
ciated vectors in mouse livers induced dysfunction in
miRNA biogenesis and caused fatality in mice [17]. Thus,
the identification of RNAi reagents that are non-cytotoxic
yet maintain potency is a critical issue for therapeutic set-
tings where siRNAs are expressed long term.
We previously identified several shRNAs that could effec-
tively downregulate CCR5 [18-20]. However, the expres-
sion of these shRNAs from a highly active U6 promoter
resulted in cytotoxicity in primary peripheral blood T-cells
but not in T-cell lines[19]. Expression from a less active
H1 promoter reduced or eliminated cytotoxicity; unfortu-
nately, these shRNAs also were reduced in potency. As
such, it was necessary to develop a means to identify shR-
NAs which are both potent and have no cytotoxicity on
primary human T-cells, if these reagents are ever to be uti-
lized in humans.
Here, we demonstrate the selection of an shRNA from a
library specific to CCR5 that maintains both potency and
lack of cytotoxicity when expressed within primary
human PBMC. We characterize this shRNA in regards to
its downregulation of CCR5 and target sequence specifi-
city.
Results
CCR5 shRNA expressed from U6 promoter are effective 
but cytotoxic to primary PBMCs
Using published algorithms[7] to predict potent shRNA
sequences, we tested 8 shRNAs expressed from the U6
promoter and directed to CCR5 (Table 1). Of these, six
showed downregulation of CCR5 in MAGI-CCR5
cells[21], ranging from 2 to greater than 10-fold. The best
four of these shRNAs were expressed using a lentiviral vec-
tor and demonstrated CCR5 reduction in primary PHA
stimulated PBMC. As previously described, cytotoxicity
was determined by monitoring the stability of shRNA
transduced cells relative to vector transduced cells over a 2
week period of culture [20]. In each case, the fraction of
EGFP+ cells (representing transduced cells) declined
whereas cells transduced by the vector alone were stable.
We previously correlated this cytotoxicity to the greater
level of expression from the U6 promoter compared to the
H1 promoter[20]. However, while expression from the
H1 promoter resulted in little or no loss in the fraction of
transduced cells, the extent of CCR5 downregulation was
also substantially reduced, rendering these shRNAs inade-
quate for ablation of CCR5 expression.
Construction of a CCR5 shRNA library and identification 
of a potent CCR5 shRNA expressed by the H1 promoter
Since screening for several shRNAs predicted by commer-
cially available algorithms were ineffective to downregu-
late CCR5 without causing cytotoxicity, we adopted a
different approach – constructing an shRNA library[22]
representing all predicted shRNAs directed against CCR5
and expressed by the H1 promoter. 3000 independent
clones were generated. Sequence analysis of 12 were ran-
domly selected clones confirmed the random representa-
tion of the library for CCR5 sequences. The shRNA
sequences of the library were tested by recloning into aPage 2 of 11
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engineered to ectopically express high levels of CCR5[23].
CCR5 downregulation was monitored by flow cytometry.
Out of 380 sequences screened from the library, we iden-
tified a single CCR5 shRNA [CCR5 shRNA (1005)] (target
sequence- 5'GAGCAAGCUCAGUUUACACC3') which
effectively downregulated CCR5 in CEM.NKR-CCR5 cells.
This CCR5 shRNA was also effective in downregulating
CCR5 in PBMC, with levels of downregulation compara-
ble to or greater than that observed with previous CCR5
shRNA expressed from the U6 promoter.
Comparison of CCR5 shRNA1005 expression from H1 
versus U6 promoter
Our previous results indicate that the higher levels of
shRNA expression driven by the U6 promoter resulted in
cytotoxicity. Since CCR5 shRNA (1005) is expressed by
the H1 promoter, we wanted to know whether it also
exhibited reduced cytotoxicity. We determined whether
CCR5 shRNA (1005) had toxicity to primary T-cells (Fig-
ure 1). Over time the EGFP+ cells maintained relatively
constant indicating no significant cytotoxicity. The lack of
apparent cytotoxicity could be due to either the lower
expression levels from the H1 promoter or the specific
Table 1: shRNA target sites and the efficiency of CCR5 reduction in MAGI-CCR5 cells
Target region Target sequence Nucleotide position CCR5 reduction on MAGI-CCR5
CCR5-1 aagtgtcaagtccaatctatgac 13 +++
CCR5-2 aagagcatgactgacatctacct 186 ++
CCR5-3 ctgacaatcgataggtacctggc 366 -
CCR5-4 gtgacaagtgtgatcacttgggt 442 -
CCR5-5 ttgtcatggtcatctgctactgg 624 ++
CCR5-6 cagtagctctaacaggttggaca 809 +
CCR5-7 aaggtcttcattacacctgcagc 517 +/-
CCR5-8 aagttcagaaactacctcttagt 909 +++
Eight shRNAs against human CCR5 were selected by a published algorithm[7]. shRNA target sequences are shown in the second column. 
Corresponding nucleotide positions of the target sequence in CCR5 mRNA are shown in the 3rd column. MAGI-CCR5 cells were transduced with 
lentiviral vectors expressing shRNA under the U6 promoter. To determine the expression levels of CCR5 on cell surface, the cells were cultured 
for 4 days and stained with APC conjugated anti-human CCR5 monoclonal antibody. The reduction levels of in EGFP+ population was analyzed by 
flow cytometry and shown as following criteria (+++ more than 10 fold reduction, ++ 10 fold reduction, + 3–5 fold reduction, +/- 2 fold reduction, 
– no reduction).
CCR5 shRNA (1005) is less cytotoxic to PBMC by expressing from the H1 promoterFigure 1
CCR5 shRNA (1005) is less cytotoxic to PBMC by expressing from the H1 promoter. PHA/IL-2-stimulated PBMCs 
(4 × 105) were transduced at m.o.i. of 5, 1 or 0.2 with lentiviral vectors encoding CCR5 shRNA (1005) under the H1 [H1 
CCR5shRNA (1005)] or the U6 promoter [U6 CCR5 shRNA (1005)] or no shRNA (no shRNA). The expression levels of 
EGFP were monitored by flow cytometry at day 4, 7 and 12 post transduction. Rectangle, m.o.i. = 5; diamond, m.o.i. = 1; trian-
gle, m.o.i. = 0.2.Page 3 of 11
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expressed using the U6 promoter, we observed a signifi-
cantly greater relative loss of EGFP+ cells. An NCBI Blast
search indicated homology only to human CCR5, so the
cytotoxicity is not a result of complete homology to other
genes, although we cannot exclude off-target effects due to
incomplete complementarity. Therefore, the reduced
cytotoxicity does not appear to be an intrinsic feature of
the sequence of this shRNA but rather due to the lower
expression levels sufficient to achieve efficient downregu-
lation.
Since CCR5 shRNA (1005) was selected by a non-conven-
tional means we further determined whether its func-
tional and structural properties resembled that of typical
shRNAs.
Target site sequence of CCR5 shRNA1005
The use of commercial (Dharmacon Research, Inc[24],
Invitrogen[25] and published algorithms[26]) and MIT
Whitehead Institute[27] siRNA Selection Program, [28-
30] to predict effective siRNA sequences did not result in
identification of the same sequence which we identified in
CCR5 shRNA (1005). Indeed, the sequence identified
here has several features not typically found using pub-
lished prediction algorithms. For example, using the crite-
ria of Reynolds et.al. [29], the sequence of CCR5 shRNA
(1005) is a poor candidate for an effective siRNA. The GC
content is within the favored 30–52%, however of eight
key criteria, six are deficient: having at least 3 A/U base
pairs at positions 15–19, an A at position 3, a U at posi-
tion 10, an G at position 13, presence of A and lack of G,
C at position 19.
One algorithm (Sfold[26]) predicted an siRNA sequence
similar to the sequence of CCR5 shRNA (1005), but hav-
ing an additional C at the 5' end and two nucleotides
deleted from the 3' end. Another algorithm (Invitrogen,
Stealth[25]) predicts a sequence with the additional C at
the 5' end and four additional nucleotides at the 3' end.
These sequences would not be predicted to be effective as
shRNAs as opposed to siRNAs, since pol III expression
generally requires a purine nucleotide at the +1 position
for efficient transcription.
The stringency of target sequence selection for RNAi activ-
ity of CCR5 shRNA (1005) was further demonstrated by
constructing an shRNA with deletion of a single nucle-
otide from the 3' end of the CCR5 shRNA (1005) sense
sequence. This resulted in complete loss of activity (data
not shown).
CCR5 downregulation by shRNA 1005 correlates with 
decreased levels of mRNA
shRNAs and siRNAs act principally by degradation of the
target mRNA [31-33]. We determined whether CCR5
shRNA (1005) acted through a similar mechanism of
action by measuring levels of CCR5 mRNA in the presence
and absence of CCR5 shRNA (1005) (Figure 2). 293T cells
ectopically expressing CCR5 were transduced with CCR5
shRNA (1005) or a control irrelevant shRNA. Downregu-
lation of cell surface CCR5 was observed as expected. Real
time RT-PCR was used to measure the levels of mRNA.
The mRNA levels decreased approximately 5-fold con-
cordant with the decrease in mean fluorescent intensity of
cell surface CCR5 expression. Thus, CCR5 shRNA (1005)
acts through a mechanism of action consistent with that
of other shRNAs.
Efficient downregulation of CCR5 shRNA (1005) requires a 
short hairpin structure
The double stranded stem of the CCR5 shRNA (1005)
sequence joined by a 9 nt loop is the structure typically
used for shRNA constructs. In some studies, the sense and
antisense of the double strand effector siRNA can be
expressed independently within the same cell, although
the level of activity is generally lower[34]. We tested the
independent expression of sense and antisense CCR5
effector sequences in the same vector but with independ-
ent promoters (Figure 3). Although we observed very
weak downregulation of CCR5 when sense and antisense
were both expressed with the U6 promoter, it was consid-
erably less effective than when expressed as a short hair-
pin. Thus, the short hairpin structure is more effective,
presumably because of more efficient formation of dou-
ble strand siRNA from a hairpin precursor as opposed to
kinetic reassociation of sense and antisense following
independent expression of each. U6 expression of anti-
sense siRNA sequences alone was completely ineffective,
demonstrating that the observed downregulation is not
likely to be a result of antisense mechanisms.
Target sequence specificity
We confirmed that the CCR5 shRNA (1005) acts specifi-
cally upon its homologous target sequence by construct-
ing a vector which expresses a chimeric mRNA consisting
of an EGFP reporter gene followed immediately by CCR5
sequences of the 20-nucleotide predicted target sequence
(Figure 4). Expression of this reporter is specifically
ablated in the presence of CCR5 shRNA (1005). Downreg-
ulation is dependent upon the presence of the target
sequence fused to EGFP; EGFP vectors without the target
sequence are not affected in expression of EGFP.Page 4 of 11
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sequence ablates activity
We further assessed the specificity of CCR5 shRNA (1005)
by mutating the shRNA within its core domain, disrupting
the complete homology with the target sequence (Figure
5). A 3-nucleotide substitution rendered the shRNA inca-
pable of downregulating CCR5 as assayed by cell surface
loss of CCR5 expression in primary PHA stimulated
PBMC. Thus, complete homology between the siRNA and
target sequence is required for activity, consistent with
RNAi mechanisms of action.
HIV-1 inhibition by CCR5 shRNA (1005) in human PBMC
To examine HIV-1 inhibition by CCR5 shRNA (1005), we
transduced PHA/IL2 activated, CD8+ cell- depleted PBMC
with the vector expressing CCR5 shRNA (1005) from the
H1 promoter. CCR5 shRNA (1005) efficiently reduced
CCR5 expression in the EGFP+ population (Figure 6).
Transduced cells were infected with the CCR5 tropic
reporter HIV-1NFNSXHSA. These reporter viruses were mod-
ified to express murine heat stable antigen (HSA) cell sur-
face marker gene in place of the HIV-1 accessory gene Vpr,
which allows the detection of HIV-1 infected cells (HSA+)
by flow cytometry. We stained HIV infected cells with
monoclonal antibodies against HSA and examined HSA
expression in EGFP+ population. HSA expression was
inhibited in the EGFP+ population in the CCR5 shRNA
(1005) vector transduced PBMC, indicating CCR5 reduc-
tion induced by CCR5 shRNA (1005) was sufficient to
inhibit HIV infection. In contrast, HSA expression was not
inhibited in the EGFP+ population in the non-shRNA
expressing control vector (FG11F) transduced PBMC.
These results demonstrated inhibition of CCR5 tropic
HIV-1 by CCR5 shRNA (1005).
Discussion
In this report, we demonstrate that a potent shRNA
directed to CCR5 with minimal cytotoxicity can be
selected from a library of CCR5 target sequences. This
shRNA is relatively rare, identified after screening 380
sequences, as opposed to a frequency of approximately 1
out of 3 effective shRNAs identified through conventional
The decreased levels of CCR5 expression by CCR5 shRNA (1005) correlates with that of CCR5 mRNAFigur  2
The decreased levels of CCR5 expression by CCR5 shRNA (1005) correlates with that of CCR5 mRNA. 
huCCR5-293T cells were transduced with lentiviral vectors bearing either shRNA 1005 against CCR5 {CCR5shRNA (1005)} 
or a control shRNA against firefly luciferase (Luc shRNA). To monitor the expression levels of CCR5 on cell surface, the cells 
were cultured for 4 days and stained with either PE-Cy5 conjugated anti human CCR5 monoclonal antibody or isotype control. 
CCR5 and EGFP expression were analyzed by flow cytometry. The percentage number in each quadrant is indicated in each 
panel (A). To measure the levels of CCR5 mRNA, total RNA was isolated using Qiagen RNeasy extraction kit. Quantitative 
RT-PCR was performed using IQ5 with iScript one step RT-PCR kit using β-actin as an internal control (B).Page 5 of 11
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selected by more conventional means, this shRNA is
dependent upon the double strand structure of the RNA
and has specific target site specificity. Most importantly,
this shRNA shows no obvious cytotoxicity and is effective
at downregulating CCR5 in primary cells.
The frequency at which we obtained CCR5 shRNA (1005)
was considerably lower than that using conventional algo-
rithms. These algorithms predict potentially potent
shRNA expressed using efficient expression vectors or
direct transfection of chemically synthesized siRNA; in
both cases, high levels of siRNA are present within the
cells. Under those conditions, in our hands, all RNAi
sequences identified have some cytotoxicity in sensitive
primary human lymphocytes when expressed from a U6
promoter. We deliberately screened for potent shRNAs
that have low levels of expression, hypothesizing that
those RNAs should have lower cellular toxicity. It is note-
worthy that the sequence of CCR5 shRNA (1005) does
not fit most of the favored rules for identification of effec-
tive shRNAs, suggesting that shRNAs obtained by func-
tional screening for potency at lower levels of expression
may have different sequence requirements. We have not
characterized the specific siRNA species derived within the
cells by DICER processing of the shRNA. A related shRNA
Efficient reduction requires short hairpin structure and the mode of action is consistent with RNAiFigure 3
Efficient reduction requires short hairpin structure and the mode of action is consistent with RNAi. huCCR5-
293T cells (0.5 × 105) were plated into 24 well plates one day before infection. Cells were transduced with lentiviral vectors 
for 2 hrs in the presence of 8 μg/mL polybrene. The transduced cells were harvested 3 days later and stained with APC conju-
gated anti-human CCR5 monoclonal antibody for flow cytometry. The efficiency of CCR5 reduction was compared in EGFP+ 
cells transduced by lentiviral vectors expressing no shRNA (negative control), CCR5 shRNA driven by the U6 {U6-shRNA 
(1005)} or the H1 promoter {H1-shRNA (1005)}, sense and antisense siRNA expressed from independent U6 promoters from 
a vector (U6-sense U6-antisense siRNA) or (U6-antisense siRNA). The x axis indicates EGFP expression; the y axis indicates 
CCR5 expression. The percentage of cells in each quadrant is shown. The quadrant lines were defined by mock-transduction 
cells. Mock: uninfected cell.
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same loop sequence was processed correctly to a 22 nucle-
otide species in rhesus macaque PBMC[19].
Thus, under experimental conditions where cytotoxicity
may be an issue, identification of shRNAs that maintain
potency, but with reduced cytotoxicity is possible, but
considerably more sequences will need to be assayed.
Nevertheless, these studies provide confidence that effec-
tive shRNAs can be obtained for long term therapeutic
purposes such as for use in stem cell gene therapy.
Conclusion
We characterized the function and structure of a potent
shRNA against CCR5 selected by library screening. This
shRNA has unique characteristics in regards to its function
and structure. The sequence of CCR5 shRNA (1005) did
not fit most of the favored rules for identification of effec-
tive shRNAs, suggesting that shRNAs obtained by func-
tional screening for potency at lower levels of expression
may have different sequence requirements.
Methods
Vector construction
The lentiviral vector encoding CCR5 shRNA (1005) under
the human H1 RNA polymerase III promoter was previ-
ously described[19].
To express CCR5 shRNA (1005) from the human U6 RNA
Polymerase III promoter, two complementary DNA oli-
gos, sense 5'-
GATCCCCGAGCAAGCTCAGTTTACACCTTGTCCGACG-
Target site specific inhibition using a chimeric EGFP-CCR5 siRNA target site (20 nt) fusion mRNAFigure 4
Target site specific inhibition using a chimeric EGFP-CCR5 siRNA target site (20 nt) fusion mRNA. 293T cells 
were co-transfected with CCR5 shRNA (1005) encoding lentiviral vector plasmid DNA and either EGFP-CCR5 siRNA target 
(EGFP CCR5 target) or EGFP-encoding lentiviral vector (EGFP) by calcium phosphate transfection. The cells were cultured for 
2 days and the EGFP expression was measured by flow cytometry. The results are exhibited as forward scatter linear (FS lin) vs 
EGFP dot plots. The quadrant lines were defined by mock-transfected 293T cells (data not shown) and the percentage num-
bers are indicated. Mean fluorescent intensity (MFI) of transfected cells is indicated at the top of each panel.Page 7 of 11
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TCGAGAAAAAGAGCAAGCTCAGTTTACACCGTCG-
GACAAGGTGTAAACTGAGCTTGCTCGGG-3', were syn-
thesized, annealed, and inserted between BbsI and XhoI
sites downstream of the U6 promoter of pBS-hU6 plasmid
DNA[18] {designed as pBS-hU6 CCR5 shRNA (1005)}.
The DNA fragment containing U6 promoter and CCR5
shRNA (1005) was excited from pBS-hU6 CCR5 shRNA
(1005) by XbaI/XhoI digestion and cloned into the same
sites of FG12[18].
To express either sense or antisense strand of CCR5 siRNA
(1005) by the U6 promoter, U6 promoter containing
either strand was amplified by PCR using following
primer pairs: for the antisense strand of CCR5 siRNA
(1005); 5'-CTCGAGTCTAGAGAATTCCCCCAGTGGAAA-
GAC-3' and 5'-GAATTCCTCGAGGCTAGCAAAAAGAGCA
AGCTCAGTTTACACCGGTGTTTCGTCCTTTCCAC-3', for
the sense strand of CCR5 siRNA (1005); 5'-CTC-
GAGTCTAGAGAATTCCCCCAGTGGAAAGAC-3' and 5'-
ACTAGTCTCGAGAAAAAGGTGTAAACTGAGCTT-
GCTCGGTGTTTCGTCCTTTCCAC-3'. The amplified PCR
fragments were digested with XbaI and XhoI and cloned
into the corresponding sites of pBS-SKII vector (Strata-
gene) and FG12.
The lentiviral vector expressing EGFP-CCR5 target chi-
meric mRNA (EGFP-CCR5 target/FG11F), which contains
the 20 nucleotide predicted shRNA target sequence (5'-
GAGCAAGCTCAGTTTACACC-3'), was prepared by PCR
amplification using the following primers: 5'-gatcggatc-
cccgggtaccggtcgccaccatggtga-3' and 5'-
GCATgaattcgatcgggtgtaaactgagcttgctcgcttacttgtacagctcgtc-
catgcc-3'. The amplified PCR fragment was digested with
BamHI and EcoRI and cloned into the corresponding sites
of the FG12 lentiviral vector. For the generation of 3-nt
mismatch mutant of CCR5 shRNA (1005) {designated as
a mutant (1005)}, entire human H1 promoter DNA in
the pBS hH1-3[18] was amplified using following prim-
ers: 5'-CTAGACCATGGAATTCGAACGCTGACG-3' and 5'-
GGTGGCTCGAGAAAAAGAGCAAGCTCTCGTTACACCG
TCGGACAAGGTGTAACGAGAGCTTGCTCG-
GGGATCCG-3'. The PCR fragment was cloned into the
FG12 between the EcoRI and XhoI sites.
Cell culture
MAGI-CCR5 cells (AIDS Research and Reference Reagent
Program of the National Institutes of Health)[21] were
maintained in DMEM supplemented with 10% FBS, 100
U/ml penicillin, 100 μg/ml streptomycin and 2 mM
glutamine.
A 3-nucleotide mutation diminishes the shRNA mediated CCR5 reductionFigure 5
A 3-nucleotide mutation diminishes the shRNA mediated CCR5 reduction. PHA/IL-2 activated PBMCs were trans-
duced with a lentiviral vector bearing either shRNA 1005 [CCR5 shRNA (1005)] or the mutant containing 3-nucleotide substi-
tution [mutant (1005)]. To monitor the expression levels of CCR5 on cell surface, the cells were cultured for 12 days and then 
stained with APC conjugated anti-CCR5 monoclonal antibody. CCR5 and EGFP expression were monitored by flow cytome-
try. The percentage number in each quadrant is indicated in each panel.
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shRNA CCR5 (1005) inhibit R5 tropic HIV-1 replication in PBMCsFigure 6
shRNA CCR5 (1005) inhibit R5 tropic HIV-1 replication in PBMCs. CD8+ cells depleted PBMCs were activated with 
PHA for 2 days. Cells were transduced with either shRNA CCR5 (1005) expressing vector or non-shRNA control vector 
(FG11F). Vector transduced cells were cultured in IL-2 containing medium and infected with either R5 tropic reporter HIV-
1NFNSXHSA (A). After 3 days infection, cells were harvested and examined for CCR5 expression in EGFP+ vector transduced 
population in the upper panel, and HSA expression in EGFP+ vector transduced population by flow cytometry.
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Genetic Vaccines and Therapy 2009, 7:8 http://www.gvt-journal.com/content/7/1/8huCCR5-293T cells were created by infecting 293T cells
with a VSV-G pseudotyped human CCR5 expressing
pBABE-huCCR5 retroviral vector (AIDS Research and Ref-
erence Reagent Program of the National Institutes of
Health)[35] followed by puromycin selection (1 μg/ml)
and maintained in IMDM, 2%FCS and 8% FBS.
Human primary PBMCs were isolated from leukopacks by
Ficoll-Paque PLUS (GE Healthcare) purification and stim-
ulated by 2.5 μg/ml of PHA for 2 days. PBMCs were cul-
tured in RPMI 1640 medium containing 20% FCS and 20
units/ml IL-2 (Roche).
Lentiviral vector production
All lentiviral vectors were produced by calcium phosphate
transfection of 293T cells as previously described[18]. The
culture supernatants were harvested on day 2 post-trans-
fection and lentiviral vector particles were concentrated
300-fold by ultracentrifugation.
Lentivirus vector transduction and HIV-1 Infection
huCCR5-293T cells and MAGI-CCR5 cells were plated
into 24 well plates one day before infection. PHA/IL-2
activated PBMCs (4 × 105) were plated into 96 well plates.
Cells were infected with lentiviral vectors at different MOI
depending on experiments for 2 hr in the presence of 8
μg/mL polybrene (Sigma). The infected cells were col-
lected 3–12 days after infection and analyzed for CCR5
and EGFP expression by flow cytometry or infected with
reporter HIV-1 as described previously[16].
Flow cytometry
Cells were stained with monoclonal antibodies against
human CCR5 (2D7; BD Biosciences), mouse IgG2a/κ iso-
type control conjugated with either PE-Cy5 or APC
according to the manufacture's instructions. For measur-
ing HIV-1 reporter virus infection, a PE-labeled anti
murine HSA mAb (M1/69, PharMingen) was used. The
cells were then fixed with 2% formaldehyde, and EGFP
and CCR5 expression were monitored on FC500 (Becton
Dickinson). The data was analyzed by CELLQUEST (Bec-
ton Dickinson) or FLOWJO (Tree Star) software.
Cotransfection
Lentiviral vector encoding EGFP-CCR5 target (1 μg) was
cotransfected with either 3 μg of CCR5 shRNA (1005)[19]
or LacZ shRNA[20] encoding pBluescript onto 293T cells
(1 × 105) in a 12-well plate. FuGENE (Roche) was used for
cotransfection according to the manufacturer's protocol.
Forty-eight hours posttransfection, cells were analyzed for
EGFP expression by flow cytometry.
Quantitative RT-PCR for CCR5 mRNA
Total RNAs from the infected CEM NKR-CCR5 cells were
isolated using the Qiagen RNeasy extraction kit following
manufacture's instruction. Quantification of mRNA was
performed using IQ5 (BioRad) with iScript one-step RT-
PCR kit and the following conditions (50°C, 10 min for
RT reaction, 95°C, 5 min for RT inactivation and activa-
tion of HotStarTaq DNA Polymerase, 40 cycles of 95°C,
15 sec, 52°C, 30 sec for PCR). RNA standards for CCR5
mRNA quantitation was made by serial dilution of in vitro
transcribed human CCR5 RNA using T7 RNA polymerase
(MEGAscript T7, Ambion). Following primers and proves
were used for RT-PCR reactions; For Human CCR5; sense
primer: gtccccttctgggctcactat, reverse primer: ccctgtcaa-
gagttgacacattgta, probe: FAM-tccaaagtcccactgggcggcag-
BHQ1, For β actin; sense primer: cgagcgcggctacagctt,
reverse primer: ccttaatgtcacgcacggatt, probe: HEX-accac-
cacggccgagcgg-BHQ1.
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